logo

Aerie Pharmaceuticals, Inc. (AERI)



Trade AERI now with
  Date
  Headline
12/3/2019 6:23:24 AM Aerie Pharma Submits Marketing Authorisation Application For Roclanda(r) 0.02%/0.005% In Europe
11/21/2019 6:35:32 AM Aerie Pharma Says EC Grants Marketing Authorisation For Rhokiinsa(r) 0.02%
11/18/2019 6:38:39 AM Aerie Pharma Agrees To Acquire Avizorex Pharma, S.L. To Advance Its Dry Eye Program
11/5/2019 6:37:07 AM Aerie Announces Positive Topline Results For Netarsudil Ophthalmic Solution In Phase 2 Study Conducted In Japan
10/24/2019 6:39:35 AM Aerie Completes Enrollment In Phase 2 Trial Of AR-1105
10/7/2019 6:40:05 AM Aerie Pharma Names Charlene Davis VP And Chief Compliance Officer
9/19/2019 6:37:33 AM Aerie Pharma Submits PAS To FDA To Allow Production Of Rocklatan 0.02%/0.005% In Athlone Ireland Facility
9/3/2019 4:05:46 PM Aerie Pharma To Offer $250 Mln Convertible Senior Notes Due 2024
8/26/2019 6:34:30 AM Aerie Pharmaceuticals Appoints Luis Vargas As Medical Director, Medical Affairs
8/20/2019 6:36:00 AM Aerie Pharma Begins First-in-Human Clinical Trial Of AR-13503
7/9/2019 6:35:11 AM Aerie Completes Enrollment Of Netarsudil Ophthalmic Solution Phase 2 Trial
4/1/2019 6:43:02 AM Aerie Appoints Gianluca Corbinelli As Chief Commercial Officer - Europe
3/25/2019 6:34:20 AM Aerie Pharma Names David Ellis Director, Chemistry; Angela Justice As Western Regional Director, Medical Science Liaison
3/21/2019 6:33:08 AM Aerie Pharma Begins Netarsudil Ophthalmic Solution Phase 2 Clinical Trial In Japan
3/18/2019 6:34:53 AM Aerie Pharma Begins Phase 2 Clinical Trial Of AR-1105 For Macular Edema Associated With Retinal Vein Occlusion
1/17/2019 6:35:00 AM Aerie Pharmaceuticals Reports Acceptance Of Investigational NDA For AR-1105
1/4/2019 6:31:10 AM Aerie Pharmaceuticals Announces Positive Topline Results Of Netarsudil Ophthalmic Solution In Pilot Phase 2 Study
1/2/2019 6:33:06 AM Aerie Pharma Appoints Ami Bavishi As Director, Investor Relations
10/9/2018 6:33:42 AM Aerie Pharma: EMA To Begin Review Of MAA For Rhokiinsa 0.02%
  
 
>